Loading clinical trials...
Loading clinical trials...
The purpose of this study is to assess the long term safety, tolerability, and immunogenicity of ACC-001, an investigational vaccine, plus QS-21 in subjects with mild to moderate Alzheimer's disease.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Pfizer
Collaborators
NCT07545473 · Dementia, Neurodegenerative Diseases, and more
NCT04570085 · Alzheimer Disease
NCT07531732 · Frontotemporal Dementia, Behavioral Variant, Alzheimer Disease
NCT07290387 · Alzheimer Disease, Dementia, and more
NCT06501495 · Aging, Alzheimer Disease
Banner Alzheimer's Institute
Phoenix, Arizona
Banner Boswell Medical Center
Sun City, Arizona
Banner Sun Health Research Institute
Sun City, Arizona
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions